- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Jeffrey Ishizuka, MD, DPhil
Melanoma and Onco-Dermatology, Medical Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
Not Applicable
Board Certified in
Internal Medicine and Medical Oncology
Biography
Jeffrey Ishizuka, MD, is a medical oncologist who treats patients with melanoma (a type of skin cancer) at Smilow Cancer Hospital.
An active researcher, Dr. Ishizuka also runs a tumor immunology lab where he seeks out new ways to use the immune system to treat cancer and benefit cancer patients.
Dr. Ishizuka earned a DPhil (doctor of philosophy, which is equivalent to a PhD), in immunology studying CD8+ T cells, a type of immune cell that is capable of attacking and killing tumor cells. These cells have been shown to be critical mediators of response to immunotherapies used in melanoma and other diseases.
He completed medical school at Harvard University, internal medicine residency at Brigham and Women’s Hospital, and medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Ishizuka is an assistant professor of medicine (oncology), pathology and immunobiology at Yale School of Medicine.
Titles
- Assistant Professor
Education & Training
- Clinical Fellow / Post-docDana-Farber Cancer Institute / Massachusetts General Hospital / Brigham and Women's Hospital (2019)
- ResidentBrigham and Women's Hospital (2015)
- MDHarvard Medical School, Medicine (2013)
- DPhilOxford University, Immunology (2008)
- BAWilliams College, Chemistry
Additional Information
Publications
- Lee D, McNamara M, Yang A, Yaskolko M, Kluger H, Tran T, Olino K, Clune J, Sznol M, Ishizuka J. Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era. Pigment Cell & Melanoma Research 2024, 37: 847-853. PMID: 39073002, DOI: 10.1111/pcmr.13188.
- Lee D, Yang A, McNamara M, Kluger H, Tran T, Olino K, Clune J, Sznol M, Ishizuka J. Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era. Journal Of Clinical Oncology 2024, 42: e21522-e21522. DOI: 10.1200/jco.2024.42.16_suppl.e21522.
- Frey A, Kerekes D, Khan S, Tran T, Kluger H, Clune J, Ariyan S, Sznol M, Ishizuka J, Olino K. Immunotherapy utilization in stage IIIA melanoma: less may be more. Frontiers In Oncology 2024, 14: 1336441. PMID: 38380358, PMCID: PMC10876869, DOI: 10.3389/fonc.2024.1336441.
- Dong M, Wang B, Wei J, de O. Fonseca A, Perry C, Frey A, Ouerghi F, Foxman E, Ishizuka J, Dhodapkar R, van Dijk D. Causal identification of single-cell experimental perturbation effects with CINEMA-OT. Nature Methods 2023, 20: 1769-1779. PMID: 37919419, PMCID: PMC10630139, DOI: 10.1038/s41592-023-02040-5.
- Rodon J, Chaney M, Cohen J, Garyantes T, Lin J, Ishizuka J, Mita A, Mita M, Muller C, Natale C, Orloff M, Papadopoulos K, Patel S, Shoushtari A. 627 The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma. 2023, a716-a716. DOI: 10.1136/jitc-2023-sitc2023.0627.
- Rodon J, Chaney M, Cohen J, Garyantes T, Ishizuka J, Lin J, Lorusso P, Mita A, Mita M, Muller C, Natale C, Orloff M, Papadopoulos K, Patel S, Shoushtari A. 1101P The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma. Annals Of Oncology 2023, 34: s663. DOI: 10.1016/j.annonc.2023.09.2235.
- Horowitch B, Lee D, Ding M, Martinez-Morilla S, Aung T, Ouerghi F, Wang X, Wei W, Damsky W, Sznol M, Kluger H, Rimm D, Ishizuka J. Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma. Clinical Cancer Research 2023, 29: 2908-2918. PMID: 37233452, PMCID: PMC10524955, DOI: 10.1158/1078-0432.ccr-23-0215.
- Bhatia A, Flamand Y, Johnson J, Ishizuka J, Duan F, Tang M, Karivedu V, Subramaniam R, Burtness B. A phase II/III trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in recurrent/metastatic head and neck cancers: ECOG-ACRIN EA3202. Journal Of Clinical Oncology 2022, 40: tps6098-tps6098. DOI: 10.1200/jco.2022.40.16_suppl.tps6098.
- Collins NB, Al Abosy R, Miller BC, Bi K, Zhao Q, Quigley M, Ishizuka JJ, Yates KB, Pope HW, Manguso RT, Shrestha Y, Wadsworth M, Hughes T, Shalek AK, Boehm JS, Hahn WC, Doench JG, Haining WN. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. Journal For ImmunoTherapy Of Cancer 2022, 10: e003402. PMID: 35264433, PMCID: PMC8915320, DOI: 10.1136/jitc-2021-003402.
- Wei J, Ishizuka JJ. Going viral: HBV-specific CD8+ tissue-resident memory T cells propagate anti-tumor immunity. Immunity 2021, 54: 1630-1632. PMID: 34380061, DOI: 10.1016/j.immuni.2021.07.014.
- Wu Z, Zhou J, Zhang X, Zhang Z, Xie Y, Liu JB, Ho ZV, Panda A, Qiu X, Cejas P, Cañadas I, Akarca FG, McFarland JM, Nagaraja AK, Goss LB, Kesten N, Si L, Lim K, Liu Y, Zhang Y, Baek JY, Liu Y, Patil DT, Katz JP, Hai J, Bao C, Stachler M, Qi J, Ishizuka JJ, Nakagawa H, Rustgi AK, Wong KK, Meyerson M, Barbie DA, Brown M, Long H, Bass AJ. Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. Nature Genetics 2021, 53: 881-894. PMID: 33972779, PMCID: PMC9124436, DOI: 10.1038/s41588-021-00859-2.
- Griffin GK, Wu J, Iracheta-Vellve A, Patti JC, Hsu J, Davis T, Dele-Oni D, Du PP, Halawi AG, Ishizuka JJ, Kim SY, Klaeger S, Knudsen NH, Miller BC, Nguyen TH, Olander KE, Papanastasiou M, Rachimi S, Robitschek EJ, Schneider EM, Yeary MD, Zimmer MD, Jaffe JD, Carr SA, Doench JG, Haining WN, Yates KB, Manguso RT, Bernstein BE. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature 2021, 595: 309-314. PMID: 33953401, PMCID: PMC9166167, DOI: 10.1038/s41586-021-03520-4.
- Griffin GK, Weirather JL, Roemer MGM, Lipschitz M, Kelley A, Chen PH, Gusenleitner D, Jeter E, Pak C, Gjini E, Chapuy B, Rosenthal MH, Xu J, Chen BJ, Sohani AR, Lovitch SB, Abramson JS, Ishizuka J, Kim AI, Jacobson CA, LaCasce AS, Fletcher CD, Neuberg D, Freeman GJ, Hodi FS, Wright K, Ligon AH, Jacobsen ED, Armand P, Shipp MA, Rodig SJ. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood 2021, 137: 1353-1364. PMID: 32871584, PMCID: PMC8555417, DOI: 10.1182/blood.2020006464.
- Grover S, Dougan M, Tyan K, Giobbie‐Hurder A, Blum SM, Ishizuka J, Qazi T, Elias R, Vora KB, Ruan AB, Martin‐Doyle W, Manos M, Eastman L, Davis M, Gargano M, Haq R, Buchbinder EI, Sullivan RJ, Ott PA, Hodi FS, Rahma OE. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis. Cancer 2020, 126: 3758-3767. PMID: 32567084, PMCID: PMC7381363, DOI: 10.1002/cncr.32966.
- Tyan K, Grover S, Dougan M, Sullivan R, Giobbie-Hurder A, Blum S, Ishizuka J, Qazi T, Elias R, Vora K, Ruan A, Martin-Doyle W, Eastman L, Davis M, Gargano M, Haq R, Buchbinder E, Ott P, Hodi F, Rahma O. Association of vitamin D intake with decreased risk of immune checkpoint inhibitor-induced colitis. Journal Of Clinical Oncology 2020, 38: 89-89. DOI: 10.1200/jco.2020.38.5_suppl.89.
- Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN. Author Correction: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nature Immunology 2019, 20: 1556-1556. PMID: 31582823, PMCID: PMC7461603, DOI: 10.1038/s41590-019-0528-5.
- Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. Journal Of Clinical Oncology 2019, 37: 2786-2794. PMID: 31461377, PMCID: PMC9798913, DOI: 10.1200/jco.19.01021.
- Konstantinopoulos P, Liu J, Luo W, Krasner C, Ishizuka J, Gockley A, Buss M, Campos S, Stover E, Wright A, Growdon W, Curtis J, Peralta A, Basada P, Quinn R, Gray K, Penson R, Cannistra S, Fleming G, Matulonis U. Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC). Journal Of Clinical Oncology 2019, 37: 5502-5502. DOI: 10.1200/jco.2019.37.15_suppl.5502.
- Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nature Immunology 2019, 20: 326-336. PMID: 30778252, PMCID: PMC6673650, DOI: 10.1038/s41590-019-0312-6.
- Ishizuka JJ, Manguso RT, Cheruiyot CK, Bi K, Panda A, Iracheta-Vellve A, Miller BC, Du PP, Yates KB, Dubrot J, Buchumenski I, Comstock DE, Brown FD, Ayer A, Kohnle IC, Pope HW, Zimmer MD, Sen DR, Lane-Reticker SK, Robitschek EJ, Griffin GK, Collins NB, Long AH, Doench JG, Kozono D, Levanon EY, Haining WN. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature 2018, 565: 43-48. PMID: 30559380, PMCID: PMC7241251, DOI: 10.1038/s41586-018-0768-9.
- Ishizuka J, Grebe K, Shenderov E, Peters B, Chen Q, Peng Y, Wang L, Dong T, Pasquetto V, Oseroff C, Sidney J, Hickman H, Cerundolo V, Sette A, Bennink JR, McMichael A, Yewdell JW. Quantitating T cell cross-reactivity for unrelated peptide antigens. Journal Of Immunology (Baltimore, Md. : 1950) 2009, 183: 4337-45. PMID: 19734234, PMCID: PMC2762195, DOI: 10.4049/jimmunol.0901607.
- Ishizuka J, Stewart-Jones GB, van der Merwe A, Bell JI, McMichael AJ, Jones EY. The structural dynamics and energetics of an immunodominant T cell receptor are programmed by its Vbeta domain. Immunity 2008, 28: 171-82. PMID: 18275829, DOI: 10.1016/j.immuni.2007.12.018.
Departments and Programs
Locations
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
Biography
Jeffrey Ishizuka, MD, is a medical oncologist who treats patients with melanoma (a type of skin cancer) at Smilow Cancer Hospital.
An active researcher, Dr. Ishizuka also runs a tumor immunology lab where he seeks out new ways to use the immune system to treat cancer and benefit cancer patients.
Dr. Ishizuka earned a DPhil (doctor of philosophy, which is equivalent to a PhD), in immunology studying CD8+ T cells, a type of immune cell that is capable of attacking and killing tumor cells. These cells have been shown to be critical mediators of response to immunotherapies used in melanoma and other diseases.
He completed medical school at Harvard University, internal medicine residency at Brigham and Women’s Hospital, and medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Ishizuka is an assistant professor of medicine (oncology), pathology and immunobiology at Yale School of Medicine.
Titles
- Assistant Professor
Education & Training
- Clinical Fellow / Post-docDana-Farber Cancer Institute / Massachusetts General Hospital / Brigham and Women's Hospital (2019)
- ResidentBrigham and Women's Hospital (2015)
- MDHarvard Medical School, Medicine (2013)
- DPhilOxford University, Immunology (2008)
- BAWilliams College, Chemistry
Additional Information
Publications
- Lee D, McNamara M, Yang A, Yaskolko M, Kluger H, Tran T, Olino K, Clune J, Sznol M, Ishizuka J. Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era. Pigment Cell & Melanoma Research 2024, 37: 847-853. PMID: 39073002, DOI: 10.1111/pcmr.13188.
- Lee D, Yang A, McNamara M, Kluger H, Tran T, Olino K, Clune J, Sznol M, Ishizuka J. Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era. Journal Of Clinical Oncology 2024, 42: e21522-e21522. DOI: 10.1200/jco.2024.42.16_suppl.e21522.
- Frey A, Kerekes D, Khan S, Tran T, Kluger H, Clune J, Ariyan S, Sznol M, Ishizuka J, Olino K. Immunotherapy utilization in stage IIIA melanoma: less may be more. Frontiers In Oncology 2024, 14: 1336441. PMID: 38380358, PMCID: PMC10876869, DOI: 10.3389/fonc.2024.1336441.
- Dong M, Wang B, Wei J, de O. Fonseca A, Perry C, Frey A, Ouerghi F, Foxman E, Ishizuka J, Dhodapkar R, van Dijk D. Causal identification of single-cell experimental perturbation effects with CINEMA-OT. Nature Methods 2023, 20: 1769-1779. PMID: 37919419, PMCID: PMC10630139, DOI: 10.1038/s41592-023-02040-5.
- Rodon J, Chaney M, Cohen J, Garyantes T, Lin J, Ishizuka J, Mita A, Mita M, Muller C, Natale C, Orloff M, Papadopoulos K, Patel S, Shoushtari A. 627 The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma. 2023, a716-a716. DOI: 10.1136/jitc-2023-sitc2023.0627.
- Rodon J, Chaney M, Cohen J, Garyantes T, Ishizuka J, Lin J, Lorusso P, Mita A, Mita M, Muller C, Natale C, Orloff M, Papadopoulos K, Patel S, Shoushtari A. 1101P The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma. Annals Of Oncology 2023, 34: s663. DOI: 10.1016/j.annonc.2023.09.2235.
- Horowitch B, Lee D, Ding M, Martinez-Morilla S, Aung T, Ouerghi F, Wang X, Wei W, Damsky W, Sznol M, Kluger H, Rimm D, Ishizuka J. Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma. Clinical Cancer Research 2023, 29: 2908-2918. PMID: 37233452, PMCID: PMC10524955, DOI: 10.1158/1078-0432.ccr-23-0215.
- Bhatia A, Flamand Y, Johnson J, Ishizuka J, Duan F, Tang M, Karivedu V, Subramaniam R, Burtness B. A phase II/III trial of chemotherapy plus cetuximab versus chemotherapy plus bevacizumab versus atezolizumab plus bevacizumab following progression on immune checkpoint inhibition in recurrent/metastatic head and neck cancers: ECOG-ACRIN EA3202. Journal Of Clinical Oncology 2022, 40: tps6098-tps6098. DOI: 10.1200/jco.2022.40.16_suppl.tps6098.
- Collins NB, Al Abosy R, Miller BC, Bi K, Zhao Q, Quigley M, Ishizuka JJ, Yates KB, Pope HW, Manguso RT, Shrestha Y, Wadsworth M, Hughes T, Shalek AK, Boehm JS, Hahn WC, Doench JG, Haining WN. PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. Journal For ImmunoTherapy Of Cancer 2022, 10: e003402. PMID: 35264433, PMCID: PMC8915320, DOI: 10.1136/jitc-2021-003402.
- Wei J, Ishizuka JJ. Going viral: HBV-specific CD8+ tissue-resident memory T cells propagate anti-tumor immunity. Immunity 2021, 54: 1630-1632. PMID: 34380061, DOI: 10.1016/j.immuni.2021.07.014.
- Wu Z, Zhou J, Zhang X, Zhang Z, Xie Y, Liu JB, Ho ZV, Panda A, Qiu X, Cejas P, Cañadas I, Akarca FG, McFarland JM, Nagaraja AK, Goss LB, Kesten N, Si L, Lim K, Liu Y, Zhang Y, Baek JY, Liu Y, Patil DT, Katz JP, Hai J, Bao C, Stachler M, Qi J, Ishizuka JJ, Nakagawa H, Rustgi AK, Wong KK, Meyerson M, Barbie DA, Brown M, Long H, Bass AJ. Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence. Nature Genetics 2021, 53: 881-894. PMID: 33972779, PMCID: PMC9124436, DOI: 10.1038/s41588-021-00859-2.
- Griffin GK, Wu J, Iracheta-Vellve A, Patti JC, Hsu J, Davis T, Dele-Oni D, Du PP, Halawi AG, Ishizuka JJ, Kim SY, Klaeger S, Knudsen NH, Miller BC, Nguyen TH, Olander KE, Papanastasiou M, Rachimi S, Robitschek EJ, Schneider EM, Yeary MD, Zimmer MD, Jaffe JD, Carr SA, Doench JG, Haining WN, Yates KB, Manguso RT, Bernstein BE. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature 2021, 595: 309-314. PMID: 33953401, PMCID: PMC9166167, DOI: 10.1038/s41586-021-03520-4.
- Griffin GK, Weirather JL, Roemer MGM, Lipschitz M, Kelley A, Chen PH, Gusenleitner D, Jeter E, Pak C, Gjini E, Chapuy B, Rosenthal MH, Xu J, Chen BJ, Sohani AR, Lovitch SB, Abramson JS, Ishizuka J, Kim AI, Jacobson CA, LaCasce AS, Fletcher CD, Neuberg D, Freeman GJ, Hodi FS, Wright K, Ligon AH, Jacobsen ED, Armand P, Shipp MA, Rodig SJ. Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma. Blood 2021, 137: 1353-1364. PMID: 32871584, PMCID: PMC8555417, DOI: 10.1182/blood.2020006464.
- Grover S, Dougan M, Tyan K, Giobbie‐Hurder A, Blum SM, Ishizuka J, Qazi T, Elias R, Vora KB, Ruan AB, Martin‐Doyle W, Manos M, Eastman L, Davis M, Gargano M, Haq R, Buchbinder EI, Sullivan RJ, Ott PA, Hodi FS, Rahma OE. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis. Cancer 2020, 126: 3758-3767. PMID: 32567084, PMCID: PMC7381363, DOI: 10.1002/cncr.32966.
- Tyan K, Grover S, Dougan M, Sullivan R, Giobbie-Hurder A, Blum S, Ishizuka J, Qazi T, Elias R, Vora K, Ruan A, Martin-Doyle W, Eastman L, Davis M, Gargano M, Haq R, Buchbinder E, Ott P, Hodi F, Rahma O. Association of vitamin D intake with decreased risk of immune checkpoint inhibitor-induced colitis. Journal Of Clinical Oncology 2020, 38: 89-89. DOI: 10.1200/jco.2020.38.5_suppl.89.
- Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN. Author Correction: Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nature Immunology 2019, 20: 1556-1556. PMID: 31582823, PMCID: PMC7461603, DOI: 10.1038/s41590-019-0528-5.
- Konstantinopoulos PA, Luo W, Liu JF, Gulhan DC, Krasner C, Ishizuka JJ, Gockley AA, Buss M, Growdon WB, Crowe H, Campos S, Lindeman NI, Hill S, Stover E, Schumer S, Wright AA, Curtis J, Quinn R, Whalen C, Gray KP, Penson RT, Cannistra SA, Fleming GF, Matulonis UA. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. Journal Of Clinical Oncology 2019, 37: 2786-2794. PMID: 31461377, PMCID: PMC9798913, DOI: 10.1200/jco.19.01021.
- Konstantinopoulos P, Liu J, Luo W, Krasner C, Ishizuka J, Gockley A, Buss M, Campos S, Stover E, Wright A, Growdon W, Curtis J, Peralta A, Basada P, Quinn R, Gray K, Penson R, Cannistra S, Fleming G, Matulonis U. Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutated recurrent/persistent endometrial cancer (EC). Journal Of Clinical Oncology 2019, 37: 5502-5502. DOI: 10.1200/jco.2019.37.15_suppl.5502.
- Miller BC, Sen DR, Al Abosy R, Bi K, Virkud YV, LaFleur MW, Yates KB, Lako A, Felt K, Naik GS, Manos M, Gjini E, Kuchroo JR, Ishizuka JJ, Collier JL, Griffin GK, Maleri S, Comstock DE, Weiss SA, Brown FD, Panda A, Zimmer MD, Manguso RT, Hodi FS, Rodig SJ, Sharpe AH, Haining WN. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nature Immunology 2019, 20: 326-336. PMID: 30778252, PMCID: PMC6673650, DOI: 10.1038/s41590-019-0312-6.
- Ishizuka JJ, Manguso RT, Cheruiyot CK, Bi K, Panda A, Iracheta-Vellve A, Miller BC, Du PP, Yates KB, Dubrot J, Buchumenski I, Comstock DE, Brown FD, Ayer A, Kohnle IC, Pope HW, Zimmer MD, Sen DR, Lane-Reticker SK, Robitschek EJ, Griffin GK, Collins NB, Long AH, Doench JG, Kozono D, Levanon EY, Haining WN. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature 2018, 565: 43-48. PMID: 30559380, PMCID: PMC7241251, DOI: 10.1038/s41586-018-0768-9.
- Ishizuka J, Grebe K, Shenderov E, Peters B, Chen Q, Peng Y, Wang L, Dong T, Pasquetto V, Oseroff C, Sidney J, Hickman H, Cerundolo V, Sette A, Bennink JR, McMichael A, Yewdell JW. Quantitating T cell cross-reactivity for unrelated peptide antigens. Journal Of Immunology (Baltimore, Md. : 1950) 2009, 183: 4337-45. PMID: 19734234, PMCID: PMC2762195, DOI: 10.4049/jimmunol.0901607.
- Ishizuka J, Stewart-Jones GB, van der Merwe A, Bell JI, McMichael AJ, Jones EY. The structural dynamics and energetics of an immunodominant T cell receptor are programmed by its Vbeta domain. Immunity 2008, 28: 171-82. PMID: 18275829, DOI: 10.1016/j.immuni.2007.12.018.
Departments and Programs
Locations
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511
- Smilow Cancer Hospital at Yale New Haven35 Park StreetNew Haven, CT 06511